吡唑并[1,5-A!吡啶-3-羰酰氯 | 78933-24-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 中文名称: 吡唑并[1,5-A!吡啶-3-羰酰氯
• 英文名称: pyrazolo[1,5-a]pyridine-3-carbonyl chloride
• 英文别名: pyrazolo[1,5-a]pyridine-3-carbonylchloride
• CAS: 78933-24-1
• 化学式: C₈H₅ClN₂O
• 分子量: 180.593
• InChiKey: OBAHAHYHAQTEHP-UHFFFAOYSA-N

物化性质

• 熔点：
  116 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.4
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  C

SDS

Name:	Pyrazolo[1 5-a]pyridine-3-carbonyl chloride Material Safety Data Sheet
Synonym:	None Known
CAS:	78933-24-1

Section 1 - Chemical Product MSDS Name:Pyrazolo[1 5-a]pyridine-3-carbonyl chloride Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
78933-24-1	Pyrazolo[1,5-a]pyridine-3-carbonyl chl	95+%	unlisted

Hazard Symbols: C
Risk Phrases: 35

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes severe burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid immediately.
Skin:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing.
Keep container tightly closed. Do not ingest or inhale. Use only in a chemical fume hood. Discard contaminated shoes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 78933-24-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: White
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 115.7 - 118.3 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H5ClN2O
Molecular Weight: 180.59

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 78933-24-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Pyrazolo[1,5-a]pyridine-3-carbonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: II
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: II
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: II

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 35 Causes severe burns.
Safety Phrases:
S 22 Do not breathe dust.
S 23 Do not inhale gas/fumes/vapour/spray.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 78933-24-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 78933-24-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 78933-24-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  吡唑并[1,5-A!吡啶-3-羰酰氯 在 二甲胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 3-(N,N-dimethyl carbamoyl)pyrazolo[1,5-a]pyridine
  参考文献：
  名称：

  Treating arthritis with 3-(N,N-dimethyl carbamoyl)pyrazolo[1,5-a]pyridine

  摘要：

  化学式为3-(N,N-二甲基甲酰胺)吡唑并[1,5-a]吡啶的新化合物具有药理特性，特别是在治疗类风湿性关节炎等关节疾病方面具有出色的效用。该化合物可通过将吡唑并[1,5-a]吡啶-3-甲酰卤（例如氯化物）与二甲胺反应制备。

  公开号：

  US04604400A1
• 作为产物：
  描述：

  吡唑并[1,5-a]吡啶-3-羧酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 吡唑并[1,5-A!吡啶-3-羰酰氯
  参考文献：
  名称：

  EphB3受体酪氨酸激酶抑制剂的构效关系研究

  摘要：

  吡唑并[1,5- a ]吡啶的 2-氯苯胺衍生物的构效关系研究表明，通过保留 2-氯苯胺并向 5吡唑并[1,5- a ]吡啶的-位。此外，用咪唑并[1,2- a ]吡啶替代吡唑并[1,5- a ]吡啶具有良好的耐受性，并导致小鼠肝微粒体稳定性增强。EphB3 抑制两种杂环系列的构效关系相似。细胞培养中的代表性类似物也证明了激酶抑制活性。一个模拟 ( 32, LDN-211904) 还分析了对一组 288 种激酶的抑制活性，发现对酪氨酸激酶具有很高的选择性。总体而言，这些研究为检查 EphB3 受体的体外、细胞和潜在的体内激酶依赖性功能提供了有用的分子探针。

  DOI：

  10.1016/j.bmcl.2009.09.010

文献信息

• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• [EN] BENZAMIDE TRPA1 ANTAGONISTS<br/>[FR] BENZAMIDES ANTAGONISTES DE TRPA1
  申请人：ACTURUM LIFE SCIENCE AB

  公开号：WO2014184235A1

  公开（公告）日：2014-11-20

  Compounds of formula I, pharmaceutically acceptable salts thereof, diastereomers, enantiomers, or mixtures thereof: wherein R, X, Y, Z, n and A are as defined in the specification, as well as pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  式I的化合物，其药用盐，非对映体，对映体或其混合物：其中R、X、Y、Z、n和A的定义如规范中所述，以及包括这些化合物的药物组合物已经准备好。它们在治疗中很有用，特别是在疼痛管理中。
• [EN] ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS<br/>[FR] INHIBITEURS DE PDE10 À L'ALCOXY TÉTRAHYDRO-PYRIDOPYRIMIDINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010138430A1

  公开（公告）日：2010-12-02

  The present invention is directed to alkoxy tetrahydro-pyridopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及一种作为治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂的烷氧基四氢吡啶嘧啶化合物。本发明还涉及利用这类化合物治疗神经学和精神疾病，如精神分裂症、精神病或亨廷顿病，以及与纹状体功能不足或基底神经节功能障碍相关的疾病。
• [EN] BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES BICYCLIQUES POUR LE TRAITEMENT D'UNE HYPERTENSION ARTÉRIELLE PULMONAIRE
  申请人：NOVARTIS AG

  公开号：WO2013030802A1

  公开（公告）日：2013-03-07

  Bicyclic heterocyclic derivatives of formula (I) useful in inhibiting PDGF receptor mediated biological activity. Wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.

  具有式(I)的二环杂环衍生物，可用于抑制血小板衍生生长因子受体介导的生物活性。其中A、R1、R1a、R2、R3、R4、R5、R6和X如本文所定义。
• [EN] IMIDAZOAZEPINONE COMPOUNDS<br/>[FR] COMPOSÉS IMIDAZOAZÉPINONES
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2011011494A1

  公开（公告）日：2011-01-27

  Compound of Formula (I) are described: Forumla (I) including pharmaceutically acceptable salts thereof, as well as pharmaceutical formulations or medicaments thereof and the use thereof in the treatment of disorders such as atherosclerosis, multiple sclerosis, psoriasis, and rheumatoid arthritis.

  化合物的化学式（I）如下所述：化学式（I）包括其药用可接受的盐，以及其药物制剂或药物，以及其在治疗动脉粥样硬化、多发性硬化、牛皮癣和类风湿性关节炎等疾病中的用途。